CA2185352A1 - Novel muteins of ifn-.beta. - Google Patents

Novel muteins of ifn-.beta.

Info

Publication number
CA2185352A1
CA2185352A1 CA002185352A CA2185352A CA2185352A1 CA 2185352 A1 CA2185352 A1 CA 2185352A1 CA 002185352 A CA002185352 A CA 002185352A CA 2185352 A CA2185352 A CA 2185352A CA 2185352 A1 CA2185352 A1 CA 2185352A1
Authority
CA
Canada
Prior art keywords
beta
ifn
muteins
those
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002185352A
Other languages
French (fr)
Other versions
CA2185352C (en
Inventor
Susan E. Goelz
Richard L. Cate
E. Pingchang Chow
R. Blake Pepinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Susan E. Goelz
Richard L. Cate
E. Pingchang Chow
R. Blake Pepinsky
Biogen, Inc.
Biogen Idec Ma, Inc.
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Susan E. Goelz, Richard L. Cate, E. Pingchang Chow, R. Blake Pepinsky, Biogen, Inc., Biogen Idec Ma, Inc., Biogen Idec Ma Inc. filed Critical Susan E. Goelz
Publication of CA2185352A1 publication Critical patent/CA2185352A1/en
Application granted granted Critical
Publication of CA2185352C publication Critical patent/CA2185352C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A IFN-.beta. mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-.beta., DNA sequences encoding these IFN-.beta. muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-.beta. mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-.beta. muteins and methods of using those compositions to treat viral infections, cancer or tumors or for immunomodulation.
CA002185352A 1994-03-15 1995-03-13 Novel muteins of ifn-.beta. Expired - Lifetime CA2185352C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/213,448 1994-03-15
US08/213,448 US5545723A (en) 1994-03-15 1994-03-15 Muteins of IFN-β
PCT/US1995/003206 WO1995025170A1 (en) 1994-03-15 1995-03-13 NOVEL MUTEINS OF IFN-$g(b)

Publications (2)

Publication Number Publication Date
CA2185352A1 true CA2185352A1 (en) 1995-09-21
CA2185352C CA2185352C (en) 2005-02-22

Family

ID=22795174

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185352A Expired - Lifetime CA2185352C (en) 1994-03-15 1995-03-13 Novel muteins of ifn-.beta.

Country Status (12)

Country Link
US (2) US5545723A (en)
EP (1) EP0750668B1 (en)
JP (2) JP3822903B2 (en)
AT (1) ATE414152T1 (en)
AU (1) AU695208B2 (en)
CA (1) CA2185352C (en)
DE (1) DE69535883D1 (en)
DK (1) DK0750668T3 (en)
FI (1) FI120356B (en)
NO (1) NO318989B1 (en)
NZ (2) NZ329970A (en)
WO (1) WO1995025170A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04266B1 (en) * 1996-12-24 2004-04-15 Biogen, Incorporated Stable liquid formulation of interferon
ES2630278T3 (en) * 1998-10-16 2017-08-21 Biogen Ma Inc. Interferon beta-1a polymer conjugates and uses thereof
ES2265693T3 (en) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. FUSION PROTEINS WITH INTERFERON-BETA AND USES.
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
YU48703A (en) 2001-02-27 2006-05-25 Maxygen Aps New interferon beta-like molecules
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CA2463935A1 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
NZ532027A (en) 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
CN105131104B (en) 2001-10-10 2018-11-16 诺和诺德公司 The reconstruct and sugar conjugation of peptide
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
NZ565990A (en) * 2002-09-27 2009-10-30 Biogen Idec Inc Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
US20040137581A1 (en) * 2002-10-01 2004-07-15 Xencor Interferon variants with improved properties
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2005211362B2 (en) 2004-02-02 2008-03-13 Ambrx, Inc. Modified human interferon polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1891224A1 (en) * 2005-05-19 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
WO2006122971A2 (en) * 2005-05-19 2006-11-23 Bayer Schering Pharma Aktiengesellschaft Treatment of disease using an improved regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
LT1917276T (en) * 2005-08-26 2018-05-25 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
US20100196328A1 (en) * 2007-04-25 2010-08-05 Tonya Bliss ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION
WO2008137471A2 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2207890A4 (en) * 2007-10-05 2010-12-15 Barofold Inc High pressure treatment of aggregated interferons
US20100158878A1 (en) * 2008-12-23 2010-06-24 Alexandra Capela Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2019073315A1 (en) 2017-10-09 2019-04-18 Mansour Poorebrahim Interferon-beta analog peptide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72786B (en) * 1980-04-03 1983-01-10 Biogen Nv Process for producing dna sequences recombinant dna molecules and human fibroplast interferon-like polypeptides
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DE3683910D1 (en) * 1986-09-05 1992-03-26 Cetus Corp OXIDATION RESISTANT MUTEINE FROM BETA-INTERFERON, THEIR PRODUCTION AND THE PREPARATIONS CONTAINING THESE MUTEINE.
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL92124A (en) * 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain non-naturally occurring phosphorylation sites
WO1993015609A1 (en) * 1992-02-05 1993-08-19 Thomas Jefferson University Interferon gene therapy for the treatment of vascular disorders

Also Published As

Publication number Publication date
NO963837D0 (en) 1996-09-13
US6127332A (en) 2000-10-03
NO963837L (en) 1996-11-14
JPH10500563A (en) 1998-01-20
MX9604073A (en) 1997-12-31
US5545723A (en) 1996-08-13
NZ283217A (en) 1998-05-27
NZ329970A (en) 2000-01-28
JP3822903B2 (en) 2006-09-20
EP0750668B1 (en) 2008-11-12
ATE414152T1 (en) 2008-11-15
CA2185352C (en) 2005-02-22
FI963630A (en) 1996-09-13
DE69535883D1 (en) 2008-12-24
FI120356B (en) 2009-09-30
AU2120295A (en) 1995-10-03
AU695208B2 (en) 1998-08-06
FI963630A0 (en) 1996-09-13
WO1995025170A1 (en) 1995-09-21
EP0750668A1 (en) 1997-01-02
NO318989B1 (en) 2005-05-30
DK0750668T3 (en) 2009-03-02
JP2006199711A (en) 2006-08-03

Similar Documents

Publication Publication Date Title
CA2185352A1 (en) Novel muteins of ifn-.beta.
DK75694A (en) Tumor necrosis factor and derivatives and mutant forms thereof;
NO914541L (en) PROCEDURE FOR MANUFACTURING TUMOR-NECROSE-FACTOR-MUTEINES
EP1440980A3 (en) Peptide analogs of human myelin basic protein
WO1995025170B1 (en) NOVEL MUTEINS OF IFN-$g(b)
NO931141L (en) TNF mutein
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
CA2250085A1 (en) Modulators of tnf receptor associated factor (traf), their preparation and use
WO2002074980A3 (en) Muteins of hypoxia inducible factor alpha and methods of use thereof
AU6808396A (en) Glial mitogenic factors, their preparation and use
DE69024104D1 (en) Polypeptides and polypeptide analogs with inhibitory activity towards human elastase
TW275066B (en)
IE871967L (en) Binding-factor-related polypeptides
AU1059095A (en) Treatment of viral disease with cd40l peptide
ATE67783T1 (en) HOMOGENEOUS RECOMBINANT IMMUNE INTERFERON FRAGMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EA200100395A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING ANTIGENIC PROTEIN COATING ANTI-ANTITROTHAL EFFECT
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
ZA873743B (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
SG128403A1 (en) Tnf-receptors, tnf binding proteins and dnas coding for them
WO1990003394A3 (en) New limphokines, dna sequences coding for said limphokines and pharmaceutical compositions containing said limphokines
AU6446190A (en) Process for inducing analgesia, peptides and therapeutic compositions
IL132632A0 (en) Dna encoding a gilr protein the protein its preparation and use
GR3025841T3 (en) An anti-hiv protein, tap 29, from trichosanthes, dna coding therefor and therapeutic uses thereof
CA2251355A1 (en) Il-6 mutein
AU4944099A (en) Adh7 nucleotides

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150313